Mergers & Acquisitions Mergers & Acquisitions

Comment: US DOJ's antitrust investigation into UnitedHealth is bad news for Amedisys deal

By Flavia Fortes and Khushita Vasant
  • 01 Mar 2024 16:39
  • 01 Mar 2024 16:39
The antitrust investigation into UnitedHealth involves concerns about monopolization through serial acquisitions, MLex has learned, complicating the chances for approval for its bid for home health and hospice provider Amedisys.
The antitrust probe was first reported by Examiner News, a local New York news outlet on Monday and by the

To view the latest version of this document and thousands of others like it, sign-in to MLex or register for a free trial.

Flavia Fortes

Global Head of Mergers


Flavia writes about merger control, antitrust enforcement and litigation in the U.S. and Brazil. Before joining MLex, Flavia worked as an Antitrust Consultant in the Federal Trade Commission's Office of International Affairs and as a Research Fellow for the American Antitrust Institute. She has written on the intersection of antitrust law and intellectual property law in technology-driven and innovative markets.

Khushita Vasant

Chief Antitrust Correspondent, US


Khushita covers US antitrust enforcement and litigation for MLex. A former Brussels hand, she wrote about about antitrust & mergers for the Policy and Regulatory Report (PaRR), she has covered the EU's actions against Google, Apple, Facebook and Amazon to name a few. Khushita specialises in tech and patent policy coverage which featured in the Concurrences Antitrust Writing Awards. Previously as a financial journalist for The Wall Street Journal and Dow Jones Newswires, she wrote about monetary policy and the bond and currency markets. Khushita studied journalism at Mumbai University, and received an Erasmus Mundus scholarship for a masters from universities in Germany and Austria.

Discover MLex

Stay on top of global regulatory developments

Latest News